novo nordisk glp-1 drugs Novo, Lilly weight-loss should be first option obesity treatments, European doctors say Novo's patent expires in India:
Description
Approved 20 years ago as a treatment for diabetes, GLP-1 drugs have been found also to help patients significantly reduce weight
2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.
These findings highlight the importance of targeted therapeutic strategies based on HF phenotypes
Moreover, the addition of finerenone to this combination therapy could potentially provide stronger cardiorenal protective benefits
NOC= Notice of Compliance.
Purpose of Review This review explores the role of GLP-1 receptor agonists (GLP-1 RAs) in addressing metabolic dysfunction and neurodegeneration in Parkinsons disease (PD), focusing on body weight regulation and neuroprotection
